Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations

Daniel Halstuch; Yaara Ber; David Margel

doi:10.1016/j.euf.2019.05.009

Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations

Eur Urol Focus. 2020 Mar 15;6(2):212-214. doi: 10.1016/j.euf.2019.05.009. Epub 2019 May 27.

Authors

Daniel Halstuch¹, Yaara Ber¹, David Margel²

Affiliations

¹ Department of Urology, Rabin Medical Center, Petah Tikva, Israel.
² Department of Urology, Rabin Medical Center, Petah Tikva, Israel; Division of Surgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: sdmargel@gmail.com.

PMID: 31147265
DOI: 10.1016/j.euf.2019.05.009

Abstract

Male carriers of BRCA mutations are at higher risk of developing prostate cancer. Many issues are still unanswered and are currently being studied, including differences between BRCA1 and BRCA2, screening and specific protocols, the role of active surveillance, and the choice of definitive treatment.

MeSH terms

BRCA1 Protein / genetics*
BRCA2 Protein / genetics*
Early Detection of Cancer*
Germ-Line Mutation*
Humans
Male
Practice Guidelines as Topic
Prostatic Neoplasms / diagnosis*
Prostatic Neoplasms / genetics
Prostatic Neoplasms / therapy*
Watchful Waiting*

Substances

BRCA1 Protein
BRCA1 protein, human
BRCA2 Protein
BRCA2 protein, human